Core Insights - Immix Biopharma, Inc. is a leader in relapsed/refractory AL Amyloidosis and will present at the Guggenheim 2nd Annual Healthcare Innovation Conference from November 10-12, 2025 [1] - The company will host one-on-one meetings with institutional investors during the conference [2] - ImmixBio's lead candidate is NXC-201, a CAR-T cell therapy, which has met its primary endpoint in an interim study [3] Company Overview - Immix Biopharma, Inc. (Nasdaq: IMMX) specializes in relapsed/refractory AL Amyloidosis and is developing NXC-201, a BCMA-targeted CAR-T cell therapy [3] - NXC-201 is currently being evaluated in the NEXICART-2 multi-center study in the U.S., with a registrational design [3] - The therapy has received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA and Orphan Drug Designation (ODD) from both the FDA and EMA [3]